
|Articles|April 1, 2003
FDA Approves Valacyclovir
San Diego - The U.S. Food and Drug Administration approved a supplemental new drug application for Valtrex (valacyclovir HCl) caplets (Glaxo SmithKline) for the suppression of recurrent genital herpes in HIV-infected individuals. Once daily dosage has been shown to reduce the transmission of symptomatic genital herpes in healthy heterosexual monogamous couples by more than three-quarters, according to Lawrence Corey, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
Dermatology Conferences and Meetings Calendar: December 2025
4
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
5


















